TTP enhances cisplatin sensitivity of squamous cell carcinoma of the head and neck (SCCHN) by inhibiting Bcl-2 expression at the post-transcriptional level, thereby enhancing cell apoptosis (39). This evidence concerns the gene BCL2 and head and neck squamous cell carcinoma.